EKF secures Japanese contract
Penarth-headquartered medical diagnostic equipment provider EKF has secured a distribution deal with Asahi Kasei, a Japanese company, to market its product in the US. Insider Media reports the product is used in measuring glycated albumin, a marker used to determine blood glucose control for people with diabetes. Measuring glycated albumin is also useful for pregnant … Continue reading EKF secures Japanese contract
Successful evaluation of EKF haemoglobin analyser
Global in vitro diagnostics company EKF Diagnostics has announced the successful evaluation of its Quo-Lab point of care HbA1c analyser by the European Reference Laboratory for Glycohemoglobin. In a recently published paper, the reference laboratory’s evaluation study assessed HbA1c (glycated haemoglobin) point of care (POC) devices using international quality targets, posing the question “Are they … Continue reading Successful evaluation of EKF haemoglobin analyser
EKF Diagnostics exploring funding for new UK business
Penarth-based EKF Diagnostics is exploring funding options for its newly formed UK business entity Renalytix AI. Insider Media reports the listed point of care business has confirmed its intention to undertake a market sounding with selected institutional investors in connection with the prospective spin-out and initial public offering (IPO) of Renalytix AI. It is expected … Continue reading EKF Diagnostics exploring funding for new UK business
EKF releases new UltraCrit training video
EKF Diagnostics has announced a new product training video for UltraCrit is now available. UltraCrit is a CLIA waived haematocrit analyser with high accuracy measurement for blood donor screening. UltraCrit uses a unique technology, developed in the US. It is the first and only haematocrit/haemoglobin device to feature ultrasound. Using the highly accurate ultrasound method … Continue reading EKF releases new UltraCrit training video
Revenues pass £40m at EKF Diagnostics
Revenues at EKF Diagnostics have passed £40m, with the medical company confident of steady and sustainable growth. Insider Media reports Penarth-headquartered EKF recorded revenues of £41.6m for the full year to December 31st 2017, up from £38.6m in 2016 in part because of the fall in the value of sterling. Adjusted earnings (EBITDA) also increased, … Continue reading Revenues pass £40m at EKF Diagnostics
EKF Diagnostics to float US division
EKF Diagnostics is raising $25m (£17.6m) to float one of its divisions in the US, then use the funds to develop artificial intelligence tracking kidney disease. The Sunday Times reports EKF hopes the new company can help it secure deals with big hospital groups across the US. RenaltyxAI will mine data from medical records and … Continue reading EKF Diagnostics to float US division
More than 30 Welsh companies attending Medica
More than thirty Welsh companies will be attending Medica as part of a Welsh Government trade mission next week. Medica attracts over 130,000 specialist visitors from over 120 countries to discover the latest innovations and trends for the medical industry. Of the Welsh companies attending, BQ reports that eighteen will also be exhibiting. Cardiff-based EKF … Continue reading More than 30 Welsh companies attending Medica
Continued good progress for EKF Diagnostics
Insider Media has reported that EKF Diagnostics’ turnover has grown by more than 20% in its half year results. According to the company’s results for the six months to June 30th 2017, turnover grew to £21.5m from £17.5m in the same period of 2016. Pre-tax profit was £1.4m, compared to a £1.2m loss the year … Continue reading Continued good progress for EKF Diagnostics
EKF issues an update on its demerger plans
EKF Diagnostics has said trading has been “comfortably ahead of budget” in the first quarter of the financial year (Insider Media, 2017). The Penarth-based medical diagnostics business has also issued an update on its plans to demerge its two divisions. In a trading update for the three months to March 31st 2017, the directors said … Continue reading EKF issues an update on its demerger plans
New test reaffirms performance criteria for EKF’s Quo-Test
EKF Diagnostics has announced that in a newly published paper its Quo-Test point-of-care haemoglobin A1c (HbA1c) analyser has again been confirmed to meet International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) performance criteria (EKF Diagnostics, 2017). Using sigma-metrics data modelling, scientists from the European Reference Laboratory for Glycohemoglobin demonstrated that Quo-Test easily met IFCC … Continue reading New test reaffirms performance criteria for EKF’s Quo-Test
